REVIEW OF STOCK STRATEGY
We had recommended our readers to buy the stock of Aurobindo Pharma Ltd at Rs 789.15 in issue no. 3 (dated November 6, 2017). After our recommendation, the stock moved higher; however, it failed to sustain above Rs 800 mark due to selling pressure in the pharmaceuticals sector. Hence, we advised to exit the stock at Rs 790.55 on November 7, 2017 ahead of the results as history suggests that pharmaceutical stocks trade with high volatility on the earnings day.